Nemaura Medical Announced That The Nasdaq Hearings Panel Granted The Company's Request For Continued Listing Under An Exception, Which Ultimately Expires On April 1 2024 - 8K
Portfolio Pulse from Benzinga Newsdesk
Nemaura Medical, Inc. has been granted a request for continued listing on the Nasdaq under an exception, according to an 8K filing. The exception allows the company to remain listed until April 1, 2024, providing it time to comply with Nasdaq's listing requirements.

December 13, 2023 | 1:07 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Nemaura Medical, Inc. has received an extension to remain listed on the Nasdaq until April 1, 2024, as per their recent 8K filing. This extension provides the company with additional time to meet Nasdaq's listing criteria.
The extension for continued listing on Nasdaq is a positive development for Nemaura Medical, as it alleviates immediate delisting concerns and provides the company with time to work on meeting the exchange's requirements. This news is likely to be viewed positively by investors and could lead to a short-term increase in the stock price, reflecting relief and renewed confidence in the company's ability to maintain its listing status.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 100